Navigation Links
Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
Date:9/28/2011

BASKING RIDGE, N.J., Sept. 28, 2011 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the Sofinnova Japan Biopharma Partnering Conference at 2:50 p.m. JST on October 4, 2011 in Tokyo, Japan.

The presentation will include an overview of the Company's pipeline with emphasis on the lead development program, the innovative anticoagulant system REG1, including a summary of the REG1 phase 2b trial (RADAR) results.

The Sofinnova Japan Biopharma Partnering Conference connects premier biotechnology companies from North America and Europe with Japanese licensing and business development executives.

ABOUT REGADO BIOSCIENCES

Regado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely and concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, provide a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3  

Regado's lead program, the anticoagulant system REG1, consists of two agents both adminis
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences to Present at the Annual UBS Global Life Sciences Conference in New York City
2. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
3. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
4. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
5. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
6. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
7. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
8. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
9. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
10. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
11. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... MOUNTAIN VIEW, Calif., July 31, 2014 IRIDEX Corporation ... the second quarter and six months ended June 28, 2014.  ... quarter of 2014, up 15% from $9.2 million in the ... the first quarter of 2014. Revenues for the first six ... million in the first six months of last year. ...
(Date:7/31/2014)... SAN DIEGO, July 31, 2014 Tandem Diabetes Care®, ... and manufacturer of the t:slim® Insulin Pump, today reported its ... In comparing the second quarter of 2014 to ... percent to $10.3 million from $5.5 million , t:slim ... pumps In comparing six months ended June 30, ...
(Date:7/31/2014)... 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... the quarter ended June 30, 2014. Financial Results ... Revenue Total revenue for the quarter ended June 30, ... quarter ended June 30, 2013 primarily due to IMBRUVICA ® ... Total revenue for the six months ended June 30, ...
Breaking Medicine Technology:IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25
(Date:8/1/2014)... in St. Louis helps explain why brain tumors occur ... than similar tumors in females. For example, glioblastomas, the ... often in males, who suffer greater cognitive impairments than ... researchers found that retinoblastoma protein (RB), a protein known ... male brain cells than in female brain cells. , ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. 1, 2014 (HealthDay News) ... have significantly less endurance than those who weigh less, a new ... were obese, half were of normal weight -- people who were ... Obesity also was associated with less strength, increased discomfort and ... to 65 years of age -- neither improved nor reduced a ...
(Date:8/1/2014)... -- Almost 140 people die every year in ... States. But there are several simple ways ... prevention coordinator at Cincinnati Children,s Hospital Medical Center,s ... center news release. "As families begin to ... for parents and children to go over school ...
(Date:8/1/2014)... Summer is here, and with it comes the ... and they can be a pain for dogs. Animal Emergency ... their customers get rid of ticks and prevent them completely. ... the summer, which is why they are so active during ... woodland areas and carry a number of diseases, including lyme ...
(Date:8/1/2014)... and transgender individuals who want to conceive a child ... heterosexual and cisgendered peers, such as reduced fertility, but ... legal challenges to become parents. A comprehensive review of ... presented in the article " LGBT Assisted Reproduction: Current ... LGBT Health , a peer-reviewed journal from Mary ...
Breaking Medicine News(10 mins):Health News:Study reveals one reason brain tumors are more common in men 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:Expert Offers School Bus Safety Tips 2Health News:Tis the Season for Tick Prevention 2Health News:Advances in assisted reproduction create more options and new legal issues for LGBT couples 2
... subjects that they were actually losing weight.,// ,Researchers belonging ... believe that they were losing weight when in reality they ... which gave the illusion that their hands were moving inward. ... creating a new body image. , The stimulators used ...
... to new research, elderly heart failure patients in United ... but lose that advantage over time.// ,Their study ... of Internal Medicine. ,Heart failure is the most ... older in both countries. ,The authors compared process ...
... have made the task of hasseled mothers easier by revealing ... foods even when in the womb. Making the task of ... they want their babies to when they are pregnant. ... of amniotic fluid a day and it is believed that ...
... conducted by researchers at University of Texas Southwestern Medical ... problem //faced by diabetics by increasing their blood pressure. ... professor and chief of the division of nutrition and ... a high-carb diet on blood pressure with a diet ...
... that the libido of a patient may be affected ... The secretion and creation of testosterone triggered by some ... of the patient. ,For most epileptics, however, treating ... a sensible approach, experts say. ,If no drugs ...
... to a latest survey, there is a steady decline in ... // . ,The findings were presented at the ... month by researchers from Cancer Research UK and the UK ... while cancer incidence rates have remained stable, there has been ...
Cached Medicine News:Health News:Disparity In Survival Rates In US and Canadian heart Patients 2Health News:Carbohydrate-rich Diet In Diabetes Raises Blood Pressure 2
The Duran Flexible Annuloplasty System encompasses both performance and practicality....
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,407-0) or contact custom...
... Pipette is a synonym for pipetting accuracy, ... design, and superior operating comfort. Its single, ... measuring stroke and blow-out as well as ... ensures utmost accuracy and precision. Ejection sleeve ...
... The new Finnpipette Focus from Thermo Labsystems ... uncompromising performance. Advanced features such as ... fine volume adjustment on microvolumes help to ... single channel pipettes. The new interchangeable handle ...
Medicine Products: